Third-Line Sunitinib Is Effective After Sequential Therapy With Cytokines and Sorafenib in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Outcome of Third-Line Sunitinib After Sequential Therapy With Cytokines and Sorafenib in Metastatic Renal Cell Carcinoma
Mol Clin Oncol 2019 Nov 01;11(5)505-510, T Fujita, T Hirayama, M Nishi, K Matsumoto, K Yoshida, M IwamuraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.